Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials


Multicentre Study To Assess Safety And Efficacy Of Psilocybin In Patients With Treatment-Resistant Depression Following Completion Of COMP 001 And COMP 003 Trials (P-TRD LTFU)


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT04519957

Organisation Name: COMPASS Pathways

Overal Status: Recruiting

Start Date: July 20, 2020

Last Update: August 20, 2020

Lead Sponsor: COMPASS Pathways

Brief Summary: The primary objective of this study is to assess the long-term efficacy of psilocybin with respect to use of new antidepressant treatment, hospitalisations for depression, suicidality, and depressive severity rated using the Montgomery and Asberg Depression Rating Scale (MADRS) over a total of 52 weeks (compared across the 1 mg, 10 mg and 25 mg psilocybin groups from COMP 001).

Conditions:
  • Treatment Resistant Depression


Total execution time in seconds: 9.1380689144135